173 related articles for article (PubMed ID: 37943339)
21. Diagnostic value of [ 68 Ga]Ga-Pentixafor PET/CT in malignant melanoma: a pilot study.
Manafi-Farid R; Mahini M; Mirshahvalad SA; Fallahi B; Fard-Esfahani A; Emami-Ardekani A; Eftekhari M; Mousavi SA; Beiki D
Nucl Med Commun; 2024 Mar; 45(3):221-228. PubMed ID: 38214076
[TBL] [Abstract][Full Text] [Related]
22. Reduced splenic uptake on
Kraus S; Klassen P; Kircher M; Dierks A; Habringer S; Gäble A; Kortüm KM; Weinhold N; Ademaj-Kospiri V; Werner RA; Schirbel A; Buck AK; Herhaus P; Wester HJ; Rosenwald A; Weber WA; Einsele H; Keller U; Rasche L; Lapa C
Theranostics; 2022; 12(13):5986-5994. PubMed ID: 35966583
[TBL] [Abstract][Full Text] [Related]
23. Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach.
Werner RA; Weich A; Higuchi T; Schmid JS; Schirbel A; Lassmann M; Wild V; Rudelius M; Kudlich T; Herrmann K; Scheurlen M; Buck AK; Kropf S; Wester HJ; Lapa C
Theranostics; 2017; 7(6):1489-1498. PubMed ID: 28529632
[TBL] [Abstract][Full Text] [Related]
24. Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT.
Duell J; Krummenast F; Schirbel A; Klassen P; Samnick S; Rauert-Wunderlich H; Rasche L; Buck AK; Wester HJ; Rosenwald A; Einsele H; Topp MS; Lapa C; Kircher M
J Nucl Med; 2021 Oct; 62(10):1415-1421. PubMed ID: 33579803
[TBL] [Abstract][Full Text] [Related]
25. Chemokine Receptor CXCR4-Targeted PET/CT With 68Ga-Pentixafor Shows Superiority to 18F-FDG in a Patient With Waldenström Macroglobulinemia.
Luo Y; Pan Q; Feng J; Cao X; Li F
Clin Nucl Med; 2018 Jul; 43(7):548-550. PubMed ID: 29742593
[TBL] [Abstract][Full Text] [Related]
26. Preliminary evidence of imaging of chemokine receptor-4-targeted PET/CT with [
Pan Q; Luo Y; Zhang Y; Chang L; Li J; Cao X; Li J; Li F
EJNMMI Res; 2020 Aug; 10(1):89. PubMed ID: 32757068
[TBL] [Abstract][Full Text] [Related]
27. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
28. [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer--initial experience.
Lapa C; Lückerath K; Rudelius M; Schmid JS; Schoene A; Schirbel A; Samnick S; Pelzer T; Buck AK; Kropf S; Wester HJ; Herrmann K
Oncotarget; 2016 Feb; 7(8):9288-95. PubMed ID: 26843617
[TBL] [Abstract][Full Text] [Related]
29. The Role of [
Albano D; Dondi F; Bertagna F; Treglia G
Cancers (Basel); 2022 Aug; 14(15):. PubMed ID: 35954476
[TBL] [Abstract][Full Text] [Related]
30. Response assessment with the CXCR4-directed positron emission tomography tracer [
Herhaus P; Habringer S; Vag T; Steiger K; Slotta-Huspenina J; Gerngroß C; Wiestler B; Wester HJ; Schwaiger M; Keller U
EJNMMI Res; 2017 Dec; 7(1):51. PubMed ID: 28577295
[TBL] [Abstract][Full Text] [Related]
31. Comparison of [
Liu M; Chen X; Ding H; Shu Q; Zheng Y; Chen Y; Cai L
Mol Imaging Biol; 2024 Apr; ():. PubMed ID: 38627276
[TBL] [Abstract][Full Text] [Related]
32. Chemokine Receptor 4-Targeted 68Ga-Pentixafor PET/CT in Response Assessment of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: Comparison to 18F-FDG PET/CT.
Pan Q; Cao X; Luo Y; Li J; Li F
Clin Nucl Med; 2021 Sep; 46(9):732-737. PubMed ID: 34172595
[TBL] [Abstract][Full Text] [Related]
33. [
Watts A; Singh B; Singh H; Bal A; Kaur H; Dhanota N; Arora SK; Mittal BR; Behera D
Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1216-1227. PubMed ID: 36482077
[TBL] [Abstract][Full Text] [Related]
34. Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [
Serfling SE; Lapa C; Dreher N; Hartrampf PE; Rowe SP; Higuchi T; Schirbel A; Weich A; Hahner S; Fassnacht M; Buck AK; Werner RA
Mol Imaging Biol; 2022 Aug; 24(4):659-665. PubMed ID: 35312939
[TBL] [Abstract][Full Text] [Related]
35. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma.
Hoffmann M; Kletter K; Becherer A; Jäger U; Chott A; Raderer M
Oncology; 2003; 64(4):336-40. PubMed ID: 12759529
[TBL] [Abstract][Full Text] [Related]
36. CXCR4-Directed Imaging in Solid Tumors.
Werner RA; Kircher S; Higuchi T; Kircher M; Schirbel A; Wester HJ; Buck AK; Pomper MG; Rowe SP; Lapa C
Front Oncol; 2019; 9():770. PubMed ID: 31475113
[TBL] [Abstract][Full Text] [Related]
37. Head-to-head comparison of [
Ballal S; Yadav MP; Roesch F; Satapathy S; Moon ES; Martin M; Wakade N; Sheokand P; Tripathi M; Chandekar KR; Agarwal S; Sahoo RK; Rastogi S; Bal C
Eur J Nucl Med Mol Imaging; 2023 Dec; 51(1):233-244. PubMed ID: 37642703
[TBL] [Abstract][Full Text] [Related]
38. The potential utility of [
Lan L; Liu H; Wang Y; Deng J; Peng D; Feng Y; Wang L; Chen Y; Qiu L
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):963-979. PubMed ID: 34410435
[TBL] [Abstract][Full Text] [Related]
39. Assessment of Central Nervous System Lymphoma Based on CXCR4 Expression In Vivo Using 68Ga-Pentixafor PET/MRI.
Starzer AM; Berghoff AS; Traub-Weidinger T; Haug AR; Widhalm G; Hacker M; Rausch I; Preusser M; Mayerhoefer ME
Clin Nucl Med; 2021 Jan; 46(1):16-20. PubMed ID: 33208624
[TBL] [Abstract][Full Text] [Related]
40. [68Ga]Pentixafor-PET/MRI for the detection of Chemokine receptor 4 expression in atherosclerotic plaques.
Li X; Heber D; Leike T; Beitzke D; Lu X; Zhang X; Wei Y; Mitterhauser M; Wadsak W; Kropf S; Wester HJ; Loewe C; Hacker M; Haug AR
Eur J Nucl Med Mol Imaging; 2018 Apr; 45(4):558-566. PubMed ID: 28932900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
